302 related articles for article (PubMed ID: 22919875)
1. Indirect serum fibrosis markers in hepatitis C virus (HCV) infection.
Paunovic K; Stojanovic M; Dimitrijevic Z; Paunovic G; Djordjevic V; Konstantinovic L; Kostic S
Med Arch; 2012; 66(4):226-30. PubMed ID: 22919875
[TBL] [Abstract][Full Text] [Related]
2. Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy.
Liu R; Guo J; Lu Y; Zhang L; Shen G; Wu S; Chang M; Hu L; Hao H; Li M; Xie Y
Clin Exp Med; 2019 Aug; 19(3):309-320. PubMed ID: 31111345
[TBL] [Abstract][Full Text] [Related]
3. Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral treatment.
Knop V; Hofmann WP; Buggisch P; Klinker H; Mauss S; Günther R; Hinrichsen H; Hüppe D; Pfeiffer-Vornkahl H; Simon KG; Berg T; Manns MP; Friedrich-Rust M;
J Viral Hepat; 2019 Feb; 26(2):224-230. PubMed ID: 30315694
[TBL] [Abstract][Full Text] [Related]
4. The diagnostic accuracy of the Forns index, platelet count and AST to Platelet Ratio Index derived fibrosis index for the prediction of Hepatitis C virus-related significant liver fibrosis and cirrhosis.
Kayadibi H; Yasar B; Ozkara S; Serdar MA; Kurdas OO; Gonen C
Scand J Clin Lab Invest; 2014 Apr; 74(3):240-7. PubMed ID: 24460024
[TBL] [Abstract][Full Text] [Related]
5. Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C.
Martinez SM; Fernández-Varo G; González P; Sampson E; Bruguera M; Navasa M; Jiménez W; Sánchez-Tapias JM; Forns X
Aliment Pharmacol Ther; 2011 Jan; 33(1):138-48. PubMed ID: 21083589
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Usefulness of APRI and FIB-4 for the Prediction of Liver Fibrosis After Liver Transplantation in Patients Infected with Hepatitis C Virus.
Imai H; Kamei H; Onishi Y; Ishizu Y; Ishigami M; Goto H; Ogura Y
Transplant Proc; 2018 Jun; 50(5):1431-1436. PubMed ID: 29705278
[TBL] [Abstract][Full Text] [Related]
7. Liver fibrosis indices for identifying patients at low risk of developing hepatocellular carcinoma after eradication of HCV.
Toyoda H; Tada T; Tachi Y; Hirai T; Yasuda S; Honda T; Hayashi K; Ishigami M; Goto H; Kumada T
Antivir Ther; 2017; 22(3):185-193. PubMed ID: 27586087
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort.
Holmberg SD; Lu M; Rupp LB; Lamerato LE; Moorman AC; Vijayadeva V; Boscarino JA; Henkle EM; Gordon SC;
Clin Infect Dis; 2013 Jul; 57(2):240-6. PubMed ID: 23592832
[TBL] [Abstract][Full Text] [Related]
9. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index.
Bachofner JA; Valli PV; Kröger A; Bergamin I; Künzler P; Baserga A; Braun D; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens JC
Liver Int; 2017 Mar; 37(3):369-376. PubMed ID: 27678216
[TBL] [Abstract][Full Text] [Related]
10. AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C.
Güzelbulut F; Çetınkaya ZA; Sezıklı M; Yaşar B; Ozkara S; Övünç AO
Turk J Gastroenterol; 2011 Jun; 22(3):279-85. PubMed ID: 21805418
[TBL] [Abstract][Full Text] [Related]
11. Real life application of FIB-4 & APRI during mass treatment of HCV genotype 4 with directly acting anti-viral agents in Egyptian patients, an observational study.
Said M; Soliman Z; Daebes H; M El-Nahaas S; El-Serafy M
Expert Rev Gastroenterol Hepatol; 2019 Dec; 13(12):1189-1195. PubMed ID: 31702417
[No Abstract] [Full Text] [Related]
12. Validation and comparison of simple noninvasive models for the prediction of liver fibrosis in chronic hepatitis C.
Amorim TG; Staub GJ; Lazzarotto C; Silva AP; Manes J; Ferronato Mda G; Shiozawa MB; Narciso-Schiavon JL; Dantas-Correa EB; Schiavon Lde L
Ann Hepatol; 2012; 11(6):855-61. PubMed ID: 23109448
[TBL] [Abstract][Full Text] [Related]
13. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
Ogawa E; Furusyo N; Shimizu M; Ihara T; Hayashi T; Harada Y; Toyoda K; Murata M; Hayashi J
Antivir Ther; 2015; 20(2):185-92. PubMed ID: 24941012
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study.
Köksal İ; Yılmaz G; Parlak M; Demirdal T; Kınıklı S; Candan M; Kaya A; Akhan S; Aydoğdu Ö; Turgut H; Gürbüz Y; Dağlı Ö; Gökal AA; Güner R; Kuruüzüm Z; Tarakçı H; Beslen N; Erdoğan S; Özdener F; Study Group TCHC
Turk J Gastroenterol; 2018 Jul; 29(4):464-472. PubMed ID: 30249562
[TBL] [Abstract][Full Text] [Related]
15. Gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced magnetic resonance imaging for evaluating fibrosis regression in chronic hepatitis C patients after direct-acting antiviral.
Li XH; Huang R; Yang M; Wang J; Gao YH; Jin Q; Ma DL; Wei L; Rao HY
World J Gastroenterol; 2022 May; 28(20):2214-2226. PubMed ID: 35721884
[TBL] [Abstract][Full Text] [Related]
16. Do serum markers of liver fibrosis vary by HCV infection in patients with alcohol use disorder?
Sanvisens A; Muñoz A; Bolao F; Zuluaga P; Farré M; Jarrin I; Tor J; Muga R
Drug Alcohol Depend; 2018 Jul; 188():180-186. PubMed ID: 29778771
[TBL] [Abstract][Full Text] [Related]
17. [Retrospective study of FibroScan, APRI, FIB-4 and FORNS indexes compared with liver biopsy in the evaluation of liver fibrosis in patients with chronic hepatitis C monoinfection and HIV coinfection].
González Guilabert MI; Hinojosa Mena-Bernal C; del Pozo González J; del Pozo Pérez MA
Gastroenterol Hepatol; 2010; 33(6):425-32. PubMed ID: 20471720
[TBL] [Abstract][Full Text] [Related]
18. Noninvasive Measurements Predict Liver Fibrosis Well in Hepatitis C Virus Patients After Direct-Acting Antiviral Therapy.
Huang R; Rao H; Yang M; Gao Y; Wang J; Jin Q; Ma D; Wei L
Dig Dis Sci; 2020 May; 65(5):1491-1500. PubMed ID: 31654313
[TBL] [Abstract][Full Text] [Related]
19. Subgroup analysis of the predictive ability of aspartate aminotransferase to platelet ratio index (APRI) and fibrosis-4 (FIB-4) for assessing hepatic fibrosis among patients with chronic hepatitis C.
Cheng CH; Chu CY; Chen HL; Lin IT; Wu CH; Lee YK; Hu PJ; Bair MJ
J Microbiol Immunol Infect; 2020 Aug; 53(4):542-549. PubMed ID: 31831303
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C infection at a tertiary hospital in South Africa: Clinical presentation, non-invasive assessment of liver fibrosis, and response to therapy.
Abuelhassan WB; Gasim GI; Ally R; Menezes C
S Afr Med J; 2020 Aug; 110(9):920-925. PubMed ID: 32880279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
